Amgen's Q1 2015 earnings call highlights strong financial performance with a 33% earnings growth and raised guidance for the year, indicating robust operational execution. Key product performance, particularly for Prolia, XGEVA, and Kyprolis, supports the momentum. The approval and anticipated launch of new drugs like Corlanor and Repatha further bolster future prospects. Continued progress in R&D and strategic emphasis on cardiovascular field expansion provide positive outlook. Overall, the positive management tone and strategic initiatives suggest a likely positive short-term impact on the stock.

[1]